

SCIENTIFIC REPORTS

OPEN

Ultra rapid *in vivo* screening for anti-Alzheimer anti-amyloid drugs

Alba Espargaró¹, Aina Medina¹, Ornella Di Pietro², Diego Muñoz-Torrero² & Raimon Sabate¹

Received: 29 October 2015

Accepted: 02 March 2016

Published: 22 March 2016

More than 46 million people worldwide suffer from Alzheimer's disease. A large number of potential treatments have been proposed; among these, the inhibition of the aggregation of amyloid β -peptide (A β), considered one of the main culprits in Alzheimer's disease. Limitations in monitoring the aggregation of A β in cells and tissues restrict the screening of anti-amyloid drugs to *in vitro* studies in most cases. We have developed a simple but powerful method to track A β aggregation *in vivo* in real-time, using bacteria as *in vivo* amyloid reservoir. We use the specific amyloid dye Thioflavin-S (Th-S) to stain bacterial inclusion bodies (IBs), in this case mainly formed of A β in amyloid conformation. Th-S binding to amyloids leads to an increment of fluorescence that can be monitored. The quantification of the Th-S fluorescence along the time allows tracking A β aggregation and the effect of potential anti-aggregating agents.

Amyloid aggregation is linked to an increasing number of human diseases, including both non-neurologic and neurodegenerative disorders¹. These human disorders, grouped under the term "conformational diseases", include Alzheimer's (AD), Parkinson's (PD) and Huntington's (HD) diseases, frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS) or type II diabetes, among others¹. Nowadays, more than 46 million people worldwide suffer from AD and the number is predicted to exceed 130 million by 2050^{2,3}. AD is a multifactorial and highly complex process, whose pathogenesis involves multiple mechanisms⁴. However, the appearance of both, amyloid plaques –consequence of the accumulation of amyloid β -peptide (A β)– and neurofibrillary tangles –mainly formed of hyperphosphorylated forms of tau protein from neuronal microtubules– are the most prominent pathological hallmarks in the brain of AD patients, leading to neuronal cell death and tissue loss throughout the brain⁵. For years it has been discussed which is the main cause of Alzheimer's disease. Currently A β aggregation is widely accepted to be one of the main culprits of the illness^{6,7}. In this light, in the last few years the search for potential inhibitors of amyloid aggregation has become one of the most pursued therapeutic strategies in the fight against AD^{8–11}.

A large number of methods to track the amyloid aggregation have been recently proposed^{12–16}. The evaluation of potential anti-amyloid drugs is usually hampered by the lack of physiologically relevant methods that can be easily implemented in high-throughput screening. Monitoring of amyloid aggregation in cells and tissues suffers from important drawbacks arising from low protein concentration, slow aggregation process and low reproducibility¹⁷. These limitations have restricted the screening of anti-amyloid compounds to *in vitro* studies using expensive synthetic peptides¹⁷. Currently, only a handful of methods, which usually track the amyloid associated toxicity in cell lines or the amyloid aggregation *in vitro*, are used to screen anti-Alzheimer anti-amyloid drugs^{18–21}. However, the *in vitro* A β aggregation is far from *in vivo* conditions. Moreover, the cellular toxicity is not directly related to the final amyloid amount, but to the type of amyloid-like aggregates formed during the aggregation process. In fact, soluble A β oligomers, generated at the early stages of the fibrillation process, are considered the primary cytotoxic species^{1,22–24}. Because *in vivo* amyloid kinetics may provide key information about both the amyloid aggregation process, still essentially uncharacterized, and inhibition mechanisms, the development of fast, simple, reproducible *in vivo* methods could represent a breakthrough in the understanding of the amyloid aggregation process and eventually in the search for potential anti-Alzheimer anti-amyloid drugs. Bacteria represent a simple but quantitative method, which will always be closer to the *in vivo* conditions in mammals than *in vitro* and toxicity assays.

The proposed method uses bacteria as an *in vivo* reservoir to track in real-time amyloid aggregation kinetics. The use of prokaryotic systems as microbial cell factories in the production of recombinant proteins has become

¹Department of Physical Chemistry, School of Pharmacy, and Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Spain. ²Laboratory of Pharmaceutical Chemistry (CSIC Associated Unit), School of Pharmacy, and Institute of Biomedicine (IBUB), University of Barcelona, Spain. Correspondence and requests for materials should be addressed to R.S. (email: rsabate@ub.edu)




Figure 1. Th-S relative fluorescence of the amyloid band along the time-course. (a) In the absence of inhibitor. (b) In the presence of 10 μ M DP-128. (c) In the presence of 10 μ M apigenin. The dotted arrows show the maximal amyloid peak \sim 485 nm. In green and red, the initial (0 min) and final (480 min) time-course. Th-S relative fluorescence measurements were performed in triplicate and the standard errors were less than 5%.

an essential tool for the biotechnological industry and biomedical research²⁵. Over-expression of amyloid-prone proteins in bacteria entails the formation of insoluble protein aggregates called inclusion bodies (IBs)^{26,27}. Compelling evidence has unequivocally demonstrated that recombinant amyloid-prone proteins are folded in amyloid-like conformations into IBs^{26,27}. Indeed, IBs formed after the over-expression in bacteria of the major A β peptides, namely A β 40 and A β 42, have been shown to display amyloid-like structures²⁸. In this context, we have recently shown the usefulness of the amyloid specific dye Thioflavin-S (Th-S) to track the amyloid deposits of different amyloid-prone proteins in bacteria^{29,30}. The facts that (1) Th-S staining of amyloid-like structures leads to an increase in its specific fluorescence –when excited under blue light– which can be easily monitored without interfering the bacteria growth and (2) Th-S crosses membranes and penetrates into the cell without affecting amyloid aggregation, make Th-S the dye of choice for tracking amyloid aggregation *in vivo*^{29,30}. Despite the noticeable applicability of our previously reported methods in anti-amyloid drug discovery, they do not allow the quantification of the amyloid amount in cell or the amazing possibility to track in real time the *in vivo* aggregation of amyloid-prone proteins. Herein, we describe an alternative method that compiles the capacity of bacteria as physiologically relevant models for the *in vivo* study of amyloid aggregation and the ability of Th-S to stain amyloid structures, thereby enabling the quantitative *in vivo* screening of anti-amyloid drugs, both in kinetic and thermodynamic terms. Importantly, the proposed method allows to track simply but effectively the inhibitory capacity of potential anti-amyloid drugs at each stage of the aggregation process, providing direct information of the behavior of each inhibitor along the aggregation time.

Results and Discussion

A β 40 and A β 42 are the main components of the senile plaques. However, the physicochemical properties of A β 40 *e.g.* higher solubility and lower aggregation propensity relative to A β 42 – have made it the peptide of choice in kinetic *in vitro* assays. Because the over-expression of A β 42 in bacteria results in the formation of a large amount of oligomeric species²⁸, we propose here to use the A β 40 variant, which does not form oligomers in bacteria²⁸, to screen the anti-aggregation effect of two potential inhibitors of the amyloid fibril polymerization. However, A β 42 aggregation kinetics have been additionally analyzed to assess the effect of the inhibitors in both A β variants. We show herein the high efficiency and performance of our ultra rapid *in vivo* screening method for anti-Alzheimer anti-amyloid drugs in bacteria over-expressing A β 40 and A β 42 in the presence or absence of two potential inhibitors of A β aggregation; DP-128, a chlorotacrine-based inhibitor of A β 42 and tau aggregation, and apigenin, a natural flavone with demonstrated activity against insulin amyloids (structures in Supplementary Fig. 1)^{31,32}. In order to show the differences in the Th-S spectra of bacteria over-expressing or not A β (*viz.* with or without IBs containing A β in amyloid conformation, respectively) as well as the potential tracking of amyloid formation *in vivo*, we measured the kinetics of induced (over-expressing A β 40) and non-induced (non-overexpressing A β 40) bacterial cultures in the presence and absence of inhibitors, by tracking the Th-S fluorescence spectra along the time in a range from 460 to 600 nm, exciting at 440 nm. Under these conditions, the formation of A β 40 and A β 42 IBs with time leads to unequivocal changes between non-induced and induced cultures as a consequence of the Th-S staining of IBs (Supplementary Fig. 2). In the non-induced samples the maximal fluorescence of Th-S as a consequence of the interaction with bacteria is at \sim 523 nm (Supplementary Fig. 2a,c,e). However, in the induced samples without inhibitor we observe the progressive appearance of a new peak (non-observable in the non-induced samples) at \sim 495 nm, arising from the Th-S binding to gradually formed A β IBs (Supplementary Fig. 2b); Interestingly, this peak is reduced in the induced samples in the presence of inhibitors as a result of the reduction of A β aggregation (Supplementary Fig. 2d,f). When the spectra of non-induced cultures were subtracted from those of A β over-expressing cultures along the time-course, we obtained the typical amyloid band displaying a maximal peak at \sim 485 nm (Fig. 1 and Supplementary Fig. 3). Importantly, we observed a diminution of the amyloid band in the samples with inhibitor (Fig. 1b,c) in comparison with the samples without inhibitor (Fig. 1a); with this fact being indicative of a reduction of the amyloid structures in the bacterial cells that grow in the presence of inhibitors (Supplementary Fig. 3a). The relative fluorescence data at 485 nm can be transformed into amyloid concentration. To quantify the obtained peaks we built a Th-S–A β 40 standard curve using *in vitro* preformed A β 40 amyloid fibrils (Supplementary Fig. 4b,c)³³. Then, the A β 40 amount in amyloid-like conformation that is present in IBs can be easily and precisely quantified by simple interpolation of the Th-S relative fluorescence data from the time-course reaction at 485 nm in the standard curve (Fig. 2). In order to discard




Figure 2. Aβ40 amyloid concentration along the time-course kinetics and amyloid concentration at end-point of the time-course. In black, red and green, in the absence (control) and presence of 10 μM DP-128 and apigenin, respectively. Aβ40 concentrations were measured in triplicate and the standard errors were less than 5%.

differences in bacterial growth and protein expression level as a consequence of the presence of the inhibitors, we evaluated Aβ40 concentration along the time (by tricine-SDS-PAGE) (Fig. 3a and Supplementary Fig. 5) and bacterial growth (by OD at 600 nm) in the presence and absence of each inhibitor (Fig. 3b). The SDS-PAGE band corresponding to Aβ peptide has been previously identified by western blotting using 6E10 Aβ antibody²⁸. As shown in Fig. 3a,b, no significant differences in expression and growth patterns were observed, hence confirming that these inhibitors do not interfere with these parameters. In the case that the potential drug interfered with these parameters the differences would have to be taken into account to normalize further amyloid aggregation kinetics. Complementarily, we checked the Aβ40 distribution between soluble and insoluble fractions (i.e. between soluble and aggregated Aβ40) at the end-point of kinetics. As shown in Fig. 3c, Aβ40 is present almost exclusively in the insoluble fraction. Interestingly, no significant differences in the Aβ40 distribution between soluble and insoluble fractions were observed in the absence and presence of inhibitors (Fig. 3c).

Amyloid kinetics can be mechanistically described as a nucleation dependent polymerization process³⁴, wherein initially soluble species are associated forming nuclei in a thermodynamically disfavored stage, with these preformed nuclei acting as templates of soluble species that are favorably added to form first amyloid fibrils and eventually mature fibers^{34,35}. *In vitro* and *in vivo* systems are being extensively used for exploring and modeling the kinetics of Aβ aggregation, which is one of the most important target for drug discovery and development^{13,15,35–45}. Within a wide range of models, this kind of processes can be mathematically addressed as an autocatalytic reaction, considering the nucleation (k_n) and elongation (k_e) constants of the process, and associated kinetic times: lag time of the thermodynamically disfavored phase (t_0), maximal growth ($t_{1/2}$) and final time of the amyloid aggregation (t_f)³⁵. When the obtained data from the aggregation kinetics are analyzed using the autocatalytic model, the effect of each inhibitor can be easily quantified in kinetic and thermodynamic terms. Thus, k_n displays reductions of ~1.7 and ~1.5-fold in the presence of DP-128 and apigenin, respectively, leading to elongations of ~25% in t_0 for both inhibitors. Reductions in k_n rate denote an inhibitory action in the nucleation phase, i.e. the formation of amyloid nuclei is partially hindered as a consequence of the presence of the inhibitor delaying the appearance of the first amyloid-like species. In contrast, k_e^{app} is increased ~1.6 and ~2-fold in the presence of DP-128 and apigenin, respectively, but without significant changes in $t_{1/2}$ and t_f . Increments in the k_e^{app} should be interpreted as an increment in the elongation rate, i.e. as an acceleration of the elongation of the fibrils. However, this is only due to the fact that k_e^{app} has been calculated using the final Aβ40 amyloid amount of each aggregation kinetic, it being 6.0, 4.0, and 3.2 μM for the control without inhibitor, DP-128, and apigenin, respectively (Table 1). In brief, at a same elongation rate, the less monomers are available to form fibrils, the sooner the reaction ends. However, as shown in Table 1, when $[A\beta_{40}^{fibrils}] \cdot k_e$ is calculated similar k_e are obtained (~0.017 min⁻¹). In consequence, $t_{1/2}$ and t_f remain essentially unaltered in the presence of inhibitors. In kinetic terms, the obtained data suggest that both inhibitors act by delaying the amyloid aggregation and hindering the nuclei formation. In addition, the final amounts of amyloid-like Aβ40 were reduced in 33 and 46% for DP-128 and apigenin, respectively (Fig. 2 and Table 1). The obtained data show that DP-128 and apigenin act essentially in the nucleation whereas elongation is almost not altered. However, both inhibitors led to a remarkable reduction in the final amount of amyloid aggregates under our experimental conditions. As shown in Supplementary Fig. 6 Th-S staining could be directly assessed by optical fluorescence microscopy. Whereas non-induced cells do not show any Th-S fluorescence (Supplementary Fig. 6a), induced cells in the absence of inhibitor (Supplementary Fig. 6b) display high fluorescence as a consequence of Th-S staining so that the Aβ40 IBs can be easily detected. In the presence of active inhibitors the fluorescence is drastically reduced (Supplementary Fig. 6c,d) denoting a reduction of amyloid amount in IBs. Interestingly, similar inhibitions are obtained when the Aβ42 variant has been tested. Indeed, as shown in Supplementary Fig. 7, DP-128 and apigenin lead to inhibitions of Aβ42 aggregation of 28 and 45%, respectively.

In summary, the proposed method, directly tracking the Th-S relative fluorescence in bacterial cells, allows the *in vivo* monitoring of the activity of potential anti-amyloid drugs in an extremely short time (<24 h), shedding




Figure 3. A β 40 expression and bacterial growth in the absence and presence of inhibitors. (a) Protein expression in bacterial cultures along the time tracked by tricine-SDS-PAGE. (b) Bacterial growth monitored by optical density at 600 nm (OD₆₀₀); the ODs were measured in triplicate and the standard errors were less than 5%. In black, red and green, in the absence (control) and presence of 10 μ M DP-128 and apigenin, respectively. Solid and dashed lines show induced and non-induced cultures, respectively. (c) A β 40 distribution in bacteria: Total (T), soluble (S) and insoluble (I) fraction of A β 40 at end-point of kinetics.

Inhibitor	Without	DP-128 ^a	Apigenin ^a
k_n ($10^6 \cdot \text{min}^{-1}$)	200.5	118.5	135.0
k_c^{app} ($\text{M}^{-1} \cdot \text{min}^{-1}$) ^{b,c}	2723.5	4427.8	5336.5
$[\text{A}\beta_{40\text{fibrils}}] \cdot k_c$ (min^{-1})	0.0164	0.0179	0.0173
t_0 (min)	112.0	140.6	144.3
$t_{1/2}$ (min)	268.3	279.4	279.4
t_1 (min)	424.5	418.3	414.6
$[\text{A}\beta_{40\text{fibrils}}]$ (μM) ^d	6.0	4.0	3.2

Table 1. Kinetic and thermodynamic parameters of A β 40 amyloid aggregation. ^aInhibition parameters at 10 μ M of inhibitor. ^bSince A β 40 concentration is not constant along the aggregation process, the k_c are apparent. ^cIn order to calculate the k_c^{app} , the final A β 40 amyloid amount of each aggregation kinetic has been considered. ^dA β 40 concentration in amyloid conformation at end-point of the time-course.

light on the inhibitor behavior and enabling the determination of IC_{50} values if different inhibitor concentrations are used. Interestingly, the present method allows simultaneous acquisition of the kinetic and thermodynamic parameters of each process, enabling the fast classification of inhibitors by accurately quantifying their inhibitory activity in each stage of the amyloid aggregation process. The reported method could be easily adapted to real-time micro-plate readers, thereby enabling high-throughput screenings with the simultaneous tracking of up to 1536 samples. Importantly, the method can be potentially used for the screening of anti-amyloid drugs against all conformational diseases by simply changing the amyloid-prone protein over-expressed in bacteria.

Methods

Chemicals and bacterial media. DP-128, *N*-{8-[(6-chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]octyl}-5-(4-chlorophenyl)-1,2,3,4-tetrahydrobenzo[*h*][1,6]naphthyridine-9-carboxamide, was prepared as previously reported³¹. The natural flavone apigenin (4',5,7-trihydroxyflavone) and all other general chemicals were purchased from Sigma-Aldrich. Compounds for bacterial media were purchased from Pronadisa. M9 minimal medium; For 100 mL: 10 mL salts $10 \times$ (0.68 g Na_2HPO_4 , 0.30 g KH_2PO_4 , 0.05 g NaCl, 0.10 g NH_4Cl), 0.2 mL 1 M $MgSO_4$, 0.2 mL 50 mM $CaCl_2$, 2.5 mL 20% glucose and 87.1 mL H_2O .

Preparation of soluble A β 40 peptide. A β 40 (trifluoroacetic acid salt) was obtained from Bachem. A stock solution was prepared by dissolving 1 mg of A β 40 in 0.5 mL of 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), which had been dried at 4 °C over molecular sieves Type 4A and then centrifuged (15,000 g for 15 min) to remove molecular sieve dust. The solution was incubated under stirring at room temperature for 1 h in sealed vials, bath-sonicated for 30 min, and stirred for an additional hour at room temperature. Then, the solution was kept at 4 °C for 30 min to avoid solvent evaporation when aliquoting. Once the sample was aliquoted, HFIP was removed by evaporation under a gentle stream of nitrogen, leaving a slightly yellow film. The samples of soluble A β 40 peptide were frozen at -80 °C. Frozen aliquots were re-suspended in 50 μ L of anhydrous dimethyl sulfoxide (DMSO) and bath-sonicated for 10 min. Sonication was crucial to remove any traces of un-dissolved seeds that may resist solubilization. Aliquots of A β were re-suspended in 950 μ L of PBS at pH 7.4. The final buffer contained 5% (v/v) DMSO⁴⁶. The final concentration of A β was adjusted by UV absorbance considering a molar absorptivity of $1490 \text{ mol}^{-1} \cdot \text{dm}^3 \cdot \text{cm}^{-1}$ at 280 nm using a UV-2401 PC UV-Vis spectrophotometer from Shimadzu.

In vitro A β 40 aggregation. Aggregation of initially soluble A β 40 was carried out for 48 h at 37 °C and 1,400 rpm using a Thermomixer from Eppendorf. The amount of insoluble amyloid fibrils at the end-time of the reaction was quantified after centrifugation at 14,000 g for 30 min. As previously observed, the insoluble fraction represented 90% of the initial A β 40, remaining 10% as soluble³³. This correction was taken into account in the determination of the amyloid stock concentration.

The standard curve was built by sequential dilution of the stock solution. The relative fluorescence of the samples was determined using a final concentration of Th-S of 250 μ M and 75, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.8, 0.4 and 0 μ M of *in vitro* fibrils of A β 40 preformed under the same conditions as the kinetics.

Cloning and expression of A β peptide. *Escherichia coli* competent cells BL21 (DE3) were transformed with the pET28a vector from Novagen carrying the DNA sequence of A β 40 or A β 42. Because of the addition of the initiation codon ATG in front of gene, the over-expressed peptide contains an additional methionine residue at its N terminus (MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV for A β 40 and MDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA for A β 42). For overnight culture preparation, 10 mL of M9 minimal medium containing 50 μ g \cdot mL⁻¹ of kanamycin were inoculated with a single colony of BL21 (DE3) bearing the plasmid to be expressed at 37 °C. For expression of the A β peptide, 100 μ L of overnight culture (providing a starting OD₆₀₀ of 0.1–0.2) was used to inoculate 9.9 mL of fresh M9 minimal medium containing kanamycin and Th-S for a final concentration of 50 μ g \cdot mL⁻¹ and 250 μ M, respectively, and 10 μ L of the inhibitors in 10 mM stock solution DMSO. Note that in the samples without inhibitor 10 μ L of DMSO had to be added. Then, bacterial cultures were grown at 37 °C and 250 rpm. When OD₆₀₀ reached \sim 0.7, 10 μ L of isopropyl 1-thio- β -D-galactopyranoside (IPTG) at 1 M were added to induce A β over-expression. Then, 200 μ L of sample were collected every 30 min during all time-course of the kinetics and fluorescence and absorbance were determined.

As “positive control” we used induced bacterial cells bearing A β plasmid (over-expressing A β) without inhibitor, displaying the maximal potential aggregation of the A β peptide in bacteria. As “negative control” we used non-induced bacterial cells bearing A β plasmid without inhibitor, showing the minimal expression of A β in the cells. However, to discard potential effects of the inhibitor in the Th-S signal (e.g. when the inhibitor also displays certain fluorescence in Th-S range), a “negative control” of each inhibitor was performed using non-induced bacterial cells bearing A β plasmid in the presence of each inhibitor. Importantly, this is highly useful to discard potential effects of the inhibitors in the cell growth (by OD₆₀₀).

Quantification of A β 40 in amyloid conformation in bacterial cells. Because non-induced cultures display relative fluorescence in the Th-S emission range (460–600 nm) when exciting at 440 nm (Supplementary Fig. 2a,c,e), these spectra would have to be removed from Th-S fluorescence spectra of induced cultures (Supplementary Fig. 2b,d,f) to quantify the amount of A β 40 in amyloid-like conformation. Since OD₆₀₀ are known at each kinetic time, induced cultures (over-expressing A β 40) could be easily corrected by subtracting the spectrum of non-induced cells with similar OD₆₀₀, thus obtaining Th-S amyloid band (Fig. 1).

As shown in Supplementary Fig. 4b,c, the standard curve of *in vitro* A β 40 fibrils shows a linear relationship between A β 40 fibril concentration and Th-S relative fluorescence at 485 nm (the maximum of the amyloid band). The interpolation of Th-S fluorescence of *in vivo* kinetics at 485 nm in the standard curve allows the easy transformation from fluorescence into amyloid concentration.

A β 40 expression levels in bacterial cells. A β 40 concentration in cell cultures in the presence and absence of inhibitor was assessed by tricine-SDS-PAGE. 300 μ L of induced bacterial cells were collected each hour during all time-course of the kinetics. Then, the samples were concentrated by gentle centrifugation obtaining OD₆₀₀ of 8. 30 μ L of concentrated sample were added to 4 \times loading buffer (250 mM Tris-HCl pH 6.8, 10% SDS, 0.008% Bromophenol Blue, 40% glycerol and 2.86 M β -mercaptoethanol). Finally, the samples were placed at 95 °C for 10 min. Denatured samples were analyzed using 16% tricine SDS-PAGE (Fig. 3a and Supplementary Fig. 5).

In order to check the A β 40 aggregation in bacteria, soluble and insoluble protein fractions were required. Then, 1 mL of concentrated sample from the end-point of each kinetic was pelleted by centrifugation at 14,000 rpm (20 min, 4 °C). The pellet containing the cells was frozen at –80 °C for at least 2 h. Then, cell pellets were re-suspended in 1 mL of phosphate buffer saline 1 \times (PBS) and sonicated using a SONICS Vibra Cell™ from Vibra-Cell-Sonics & Materials, Inc. at 30% during 1 min (with intervals of 1 seg sonication/0.5 seg stand-by). Soluble and insoluble fractions were separated by centrifugation at 14,000 rpm (20 min, 4 °C). The insoluble fraction was re-suspended in 1 mL PBS 1 \times . Finally, the samples were analyzed by tricine-SDS-PAGE (Fig. 3c).

Thioflavin-S (Th-S) Steady-State Fluorescence. Relative fluorescence of Th-S binding to A β was checked using an Aminco Bowman Series 2 luminescence spectrophotometer from Aminco-Bowman with an excitation wavelength of 440 nm and emission range from 460 to 600 nm. The emission at 485 nm was recorded for further determination of the amyloid-like concentration. Excitation and emission slit widths of 4 nm were used and spectra were acquired at 1 nm intervals and 500 nm \cdot min^{–1} rates and 875 V⁴⁷. Importantly, in order to compare the obtained data, the voltage must always be known and not changed.

Aggregation assay analysis. The amyloid aggregation in bacteria may be studied as an autocatalytic reaction using the equation:

$$f = \frac{\rho \{ \exp[(1 + \rho) kt] - 1 \}}{1 + \rho \exp[(1 + \rho) kt]} \quad (1)$$

under the boundary condition of $t = 0$ and $f = 0$, where $k = k_a a$ (when a is the protein concentration) and ρ represents the dimensionless value to describe the ratio of k_n to k . By non-linear regression of f against t , values of ρ and k are obtained, and from them the rate constants, k_e (elongation constant) and k_n (nucleation constant)³⁵. Note that because the concentration of A β is not constant in the bacterial cells during the protein over-expression, we have arbitrarily considered as a the A β concentration of the final time-course, obtaining apparent values for k_e , which allow quantitative comparison of kinetics. The extrapolation of the linear portion of the sigmoid curve to abscissa ($f = 0$), and to the highest ordinate value of the fitted plot, afforded two values of time (t_0 and t_1), which correspond to the lag time and to the end-time reaction. The time at which half of the protein was aggregated (i.e., when $f = 0.5$) was considered the time of half-aggregation ($t_{1/2}$)³⁵.

Optical fluorescence microscopy. Bacterial cells overexpressing A β 40 were incubated 1 h with 125 μ M of Th-S. Th-S was removed by centrifugation and the cells were re-suspended in PBS twice and placed on a microscope slide. Th-S fluorescence was detected using a Leitz DMIRB microscope under UV light using a GFP filter (excitation filter BP480/40 and emission filter BP527/30)⁴⁸.

References

- Chiti, F. & Dobson, C. M. Protein misfolding, functional amyloid, and human disease. *Annu Rev Biochem* **75**, 333–366 (2006).
- Reitz, C., Brayne, C. & Mayeux, R. Epidemiology of Alzheimer disease. *Nat Rev Neurol* **7**, 137–152, doi: 10.1038/nrneurol.2011.2 (2011).
- Prince, M., Wimo, A., Guerchet, M., Ali, G.-C., Wu, Y.-T. & Prina, M. World Alzheimer Report 2015. The global impact of dementia. An analysis of prevalence, incidence, cost & trends; Alzheimer's Disease International: London, <http://www.alz.co.uk>, (2015) (Accessed:15/02/2016)
- Huang, Y. & Mucke, L. Alzheimer mechanisms and therapeutic strategies. *Cell* **148**, 1204–1222, doi: 10.1016/j.cell.2012.02.040 (2012).
- Ballard, C. *et al.* Alzheimer's disease. *Lancet* **377**, 1019–1031, doi: 10.1016/S0140-6736(10)61349-9 (2011).
- Skaper, S. D. Alzheimer's disease and amyloid: culprit or coincidence? *Int Rev Neurobiol* **102**, 277–316, doi: 10.1016/B978-0-12-386986-9.00011-9 (2012).
- Bucciantini, M. *et al.* Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. *Nature* **416**, 507–511, doi: 10.1038/416507a (2002).
- Godyn, J., Jonczyk, J., Panek, D. & Malawska, B. Therapeutic strategies for Alzheimer's disease in clinical trials. *Pharmacol Rep* **68**, 127–138, doi: 10.1016/j.pharep.2015.07.006 (2016).
- Jia, Q., Deng, Y. & Qing, H. Potential therapeutic strategies for Alzheimer's disease targeting or beyond β -amyloid: insights from clinical trials. *Biomed Res Int* **2014**, 837157, doi: 10.1155/2014/837157 (2014).
- Aisen, P. S. The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. *CNS Drugs* **19**, 989–996, doi: 10.1177/1043986205019008 (2005).
- Lannfelt, L. *et al.* Perspectives on future Alzheimer therapies: amyloid- β protofibrils-a new target for immunotherapy with BAN2401 in Alzheimer's disease. *Alzheimers Res Ther* **6**, 16, doi: 10.1186/alzrt246 (2014).
- Meyer-Luehmann, M. *et al.* Rapid appearance and local toxicity of amyloid- β plaques in a mouse model of Alzheimer's disease. *Nature* **451**, 720–724, doi: 10.1038/nature06616 (2008).
- Tokuraku, K., Marquardt, M. & Ikezu, T. Real-time imaging and quantification of amyloid- β peptide aggregates by novel quantum-dot nanoprobes. *PLoS One* **4**, e8492, doi: 10.1371/journal.pone.0008492 (2009).
- Burgold, S., Filser, S., Dorostkar, M. M., Schmidt, B. & Herms, J. *In vivo* imaging reveals sigmoidal growth kinetic of β -amyloid plaques. *Acta Neuropathol Commun* **2**, 30, doi: 10.1186/2051-5960-2-30 (2014).
- Meisl, G. *et al.* Differences in nucleation behavior underlie the contrasting aggregation kinetics of the A β 40 and A β 42 peptides. *Proc Natl Acad Sci USA* **111**, 9384–9389, doi: 10.1073/pnas.1401564111 (2014).

16. Ullah, G., Demuro, A., Parker, I. & Pearson, J. E. Analyzing and Modeling the Kinetics of Amyloid B Pores Associated with Alzheimer's Disease Pathology. *PLoS One* **10**, e0137357, doi: 10.1371/journal.pone.0137357 (2015).
17. Villar-Pique, A., Espargaro, A., Ventura, S. & Sabate, R. *In vivo* amyloid aggregation kinetics tracked by time-lapse confocal microscopy in real-time. *Biotechnol J*, doi: 10.1002/biot.201500252 (2015).
18. Xu, X. *et al.* Prevention of β -amyloid induced toxicity in human iPSC cell-derived neurons by inhibition of Cyclin-dependent kinases and associated cell cycle events. *Stem Cell Res* **10**, 213–227, doi: 10.1016/j.scr.2012.11.005 (2013).
19. Hou, X. Q. *et al.* A novel assay for high-throughput screening of anti-Alzheimer's disease drugs to determine their efficacy by real-time monitoring of changes in PC12 cell proliferation. *Int J Mol Med* **33**, 543–549, doi: 10.3892/ijmm.2013.1608 (2014).
20. Bartolini, M. *et al.* Insight into the kinetic of amyloid β (1–42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. *ChemBioChem* **8**, 2152–2161, doi: 10.1002/cbic.200700427 (2007).
21. Bartolini, M. *et al.* Kinetic characterization of amyloid- β 1–42 aggregation with a multimethodological approach. *Anal Biochem* **414**, 215–225, doi: 10.1016/j.ab.2011.03.020 (2011).
22. Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β -peptide. *Nat Rev Mol Cell Biol* **8**, 101–112, doi: nrm2101 (2007).
23. Prangkio, P., Yusko, E. C., Sept, D., Yang, J. & Mayer, M. Multivariate analyses of amyloid- β oligomer populations indicate a connection between pore formation and cytotoxicity. *PLoS One* **7**, e47261, doi: 10.1371/journal.pone.0047261 (2012).
24. Bernstein, S. L. *et al.* Amyloid- β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. *Nat Chem* **1**, 326–331, doi: 10.1038/nchem.247 (2009).
25. Ventura, S. & Villaverde, A. Protein quality in bacterial inclusion bodies. *Trends Biotechnol* **24**, 179–185, doi: S0167-7799(06)00052-7 (2006).
26. Wang, L., Maji, S. K., Sawaya, M. R., Eisenberg, D. & Riek, R. Bacterial inclusion bodies contain amyloid-like structure. *PLoS Biol* **6**, e195, doi: 10.1371/journal.pbio.0060195 (2008).
27. de Groot, N. S., Sabate, R. & Ventura, S. Amyloids in bacterial inclusion bodies. *Trends Biochem Sci* **34**, 408–416 (2009).
28. Dasari, M. *et al.* Bacterial inclusion bodies of Alzheimer's disease β -amyloid peptides can be employed to study native-like aggregation intermediate states. *ChemBioChem* **12**, 407–423, doi: 10.1002/cbic.201000602 (2011).
29. Pouplana, S. *et al.* Thioflavin-S staining of bacterial inclusion bodies for the fast, simple, and inexpensive screening of amyloid aggregation inhibitors. *Curr Med Chem* **21**, 1152–1159, doi: CMC-EPUB-56032 (2014).
30. Espargaro, A., Sabate, R. & Ventura, S. Thioflavin-S staining coupled to flow cytometry. A screening tool to detect *in vivo* protein aggregation. *Mol Biosyst* **8**, 2839–2844, doi: 10.1039/c2mb25214g (2012).
31. Di Pietro, O. *et al.* Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β -amyloid, tau, and cholinesterase pathologies. *Eur J Med Chem* **84**, 107–117, doi: 10.1016/j.ejmech.2014.07.021 (2014).
32. Amini, R., Yazdanparast, R. & Bahrakia, S. Apigenin reduces human insulin fibrillation *in vitro* and protects SK-N-MC cells against insulin amyloids. *Int J Biol Macromol* **60**, 334–340, doi: 10.1016/j.ijbiomac.2013.06.013 (2013).
33. Sabate, R. & Estelrich, J. Pinacanol as effective probe of fibrillar β -amyloid peptide: comparative study with Congo Red. *Biopolymers* **72**, 455–463, doi: 10.1002/bip.10485 (2003).
34. Jarrett, J. T. & Lansbury, P. T. Jr. Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? *Cell* **73**, 1055–1058 (1993).
35. Sabate, R., Gallardo, M. & Estelrich, J. An autocatalytic reaction as a model for the kinetics of the aggregation of β -amyloid. *Biopolymers* **71**, 190–195, doi: 10.1002/bip.10441 (2003).
36. Cohen, S. I., Vendruscolo, M., Dobson, C. M. & Knowles, T. P. Nucleated polymerization with secondary pathways. II. Determination of self-consistent solutions to growth processes described by non-linear master equations. *J Chem Phys* **135**, 065106, doi: 10.1063/1.3608917 (2011).
37. Cohen, S. I. *et al.* Nucleated polymerization with secondary pathways. I. Time evolution of the principal moments. *J Chem Phys* **135**, 065105, doi: 10.1063/1.3608916 (2011).
38. Lomakin, A., Chung, D. S., Benedek, G. B., Kirschner, D. A. & Teplow, D. B. On the nucleation and growth of amyloid β -protein fibrils: detection of nuclei and quantitation of rate constants. *Proc Natl Acad Sci USA* **93**, 1125–1129 (1996).
39. Lomakin, A., Teplow, D. B., Kirschner, D. A. & Benedek, G. B. Kinetic theory of fibrillogenesis of amyloid β -protein. *Proc Natl Acad Sci USA* **94**, 7942–7947 (1997).
40. Pallitto, M. M. & Murphy, R. M. A mathematical model of the kinetics of β -amyloid fibril growth from the denatured state. *Biophys J* **81**, 1805–1822, doi: S0006-3495(01)75831-6 (2001).
41. Murphy, R. M. & Pallitto, M. M. Probing the kinetics of β -amyloid self-association. *J Struct Biol* **130**, 109–122, doi: 10.1006/jsbi.2000.4253 (2000).
42. Murphy, R. M. Kinetics of amyloid formation and membrane interaction with amyloidogenic proteins. *Biochim Biophys Acta* **1768**, 1923–1934, doi: S0005-2736(06)00491-3 (2007).
43. Knowles, T. P. *et al.* An analytical solution to the kinetics of breakable filament assembly. *Science* **326**, 1533–1537, doi: 10.1126/science.1178250 (2009).
44. Ferrone, F. Analysis of protein aggregation kinetics. *Methods Enzymol* **309**, 256–274 (1999).
45. Cohen, S. I., Vendruscolo, M., Dobson, C. M. & Knowles, T. P. Nucleated polymerization with secondary pathways. III. Equilibrium behavior and oligomer populations. *J Chem Phys* **135**, 065107, doi: 10.1063/1.3608918 (2011).
46. Sabate, R. & Estelrich, J. Evidence of the existence of micelles in the fibrillogenesis of β -amyloid peptide. *J Phys Chem B* **109**, 11027–11032 (2005).
47. Sola, I. *et al.* Novel Levettiracetam Derivatives That Are Effective against the Alzheimer-like Phenotype in Mice: Synthesis, *in Vitro*, *ex Vivo*, and *in Vivo* Efficacy Studies. *J Med Chem* **58**, 6018–6032, doi: 10.1021/acs.jmedchem.5b00624 (2015).
48. Perez-Areales, F. J. *et al.* Shogaol-huprine hybrids: dual antioxidant and anticholinesterase agents with β -amyloid and tau anti-aggregating properties. *Bioorg Med Chem* **22**, 5298–5307, doi: 10.1016/j.bmc.2014.07.053 (2014).

Acknowledgements

This work was supported by Ministerio de Economía y Competitividad (MINECO) (SAF2014-57094-R (D.M.-T.), start-up grant of the Ramón y Cajal program RYC-2011-07987 (R.S.)), and Generalitat de Catalunya (GC) (2014SGR52 (D.M.-T. and O.D.P.) and 2014SGR938 (R.S. and A.E.)). A contract from the Juan de la Cierva program of MINECO to A.E. (JCI-2012-12193) is gratefully acknowledged.

Author Contributions

A.E., A.M. and O.D.P. performed the research. D.M.-T. drafted the manuscript and R.S. supervised the research, drafted the manuscript and edited the draft. All authors edited the final manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Espargaró, A. *et al.* Ultra rapid *in vivo* screening for anti-Alzheimer anti-amyloid drugs. *Sci. Rep.* **6**, 23349; doi: 10.1038/srep23349 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>